You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. CSF Tau Biomarker-guided Development of Hsp90 Inhibitors for Alzheimer's Disease

    SBC: YUMA THERAPEUTICS CORPORAITON            Topic: NIA

    DESCRIPTION (provided by applicant): Research and Related Other Project Information Item 7. Project Summary/Abstract Neurodegeneration in Alzheimer's disease (AD) may result from deposition of A as plaques in brain tissue. However, less effort has been made to elucidate the role of tau- containing neurofibrillary tangles (NFTs) in AD. Accumulating evidence suggests that tau containing NFTs i ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Drug regulators of nitric oxide production as Alzheimer's disease therapeutics

    SBC: Epigen Biosciences, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Druggable regulators of nitric oxide production as new Alzheimer's disease therapeutics Summary: Nitrosative stress is a critical mediator of the onset and progression of Alzheimer's disease (AD): it precedes and is associated with neuritic dystrophy and dendritic spine loss, A /amyloid accumulation and deposition, cholinergic denervation and a memory ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. A novel vaccine against vaginal Chlamydia trachomatis

    SBC: EPITOGENESIS INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Preventing Chlamydia trachomatis (Ct) infections represent a critical unmet medical need. Development of an effective vaccine would not only reduce the morbidity associated with these infections, including pelvic inflammatory disease (PID), infertility, chronic pelvic pain and ectopic pregnancy, but could also reduce collateral riss including HIV transmission. ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Redesign of the Carbapenem Scaffold

    SBC: THERAVANCE, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Carbapenemase-producing bacteria now threaten to undermine the efficacy of the carbapenems, long considered to be the most potent and reliable of the -lactam antibiotics. In Gram-negative microorganisms, in particular,the ability to produce class A serine carbapenemases, such as the plasmid-mediated KPC enzymes, or class B metallo-carbapenemases, such as the ND ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a diagnostic biomarker for Ewing's Sarcoma family of tumors.

    SBC: Entrogen, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Development of a diagnostic biomarker for Ewing's Sarcoma family of tumors Ewing's family tumors (EFTs) are characterized by recurrent chromosomal translocations that produce chimeric fusions between the EWS gene and one of five ETS transcription factors. The expression of EWS/FLI1, the predominant fusion product in EFTs, is believed to deregulate do ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. A novel diagnostic test for Irinotecan and Topotecan sensitivity

    SBC: RG Biopharma            Topic: NCI

    DESCRIPTION (provided by applicant): The long term objective of this Phase 1 study is to produce an antibody-based diagnostic assay to detect tumor responsiveness to a widely used class of chemotherapeutic agents derived from camptothecin that includes Irinotecan and Topotecan. The assay will be based on a novel biomarker associated with cellular sensitivity to camptothecin and will have clinical ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Integrin Targeted Therapy for the Treatment of Ovarian Cancer

    SBC: APPLIED INTEGRIN SCIENCES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Although prevention and early detection are the ultimate goals, the fact remains that 21,990 women in 2011 will be diagnosed with ovarian cancer in the U.S. Of these women 75% will be confronted with a high stage tumorand a five-year survival rate of 28%, which cannot be ignored. For these patients, improved treatment strategies for residual disease following s ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Devices enabling improved light delivery for photodynamic therapy of oral cancer

    SBC: LUCIFICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Oral cancer is a devastating disease that impacts 640,000 people worldwide. Though treatment with photodynamic therapy can be effective with significantly less morbidity than alternative therapies, problems arising fromless than optimal light delivery to the oral cavity have hindered its widespread application. The goal of the proposed research is to provide a ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): In the United States colorectal cancer (CRC) is the third leading cause of cancer mortality. Surgery is the primary treatment for early stage CRC; but adjuvant therapy is usually needed in advanced disease. Approximately 55% of CRC patients have metastatic disease for which the prognosis is poor despite incremental improvements due to introduction of irinotecan ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Evaluation of In Vitro Companion Diagnostic Monoclonal Antibodies for Use in a St

    SBC: INTICA BIOMEDICAL, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This project is designed to allow independent experts in the development and/or application of in vitro breast cancer diagnostic tests, Drs. Badve (breast pathologist) and Sledge (breast oncologist), to evaluate INTICA's candidate anti-DEspR mAbs to develop the preliminary materials and methods for a commercially viable companion diagnostic test. DEspR, th ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government